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Abstract
Objective: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The
aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of
acute coronary syndrome (ACS), both in-hospital phase and follow-up period.
Methods: A prospective clinical study was performed in patients with debut’s ACS. The endpoints were the development of
cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366
days, inter-quartile range: 273–519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7613.0 years,
24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were
analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were
calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX
score.
Results: The mean fluorescent AGEs and sRAGE levels were 57.7645.1 AU and 1045.46850.0 pg/mL, respectively. 19
patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were
significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding
fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction,
glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis,
whereas fluorescent AGEs was significantly associated with long-term prognosis.
Conclusions: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high
fluorescent AGE levels are associated with more follow-up events.
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Funding: This study was supported in part by the Plan Nacional Español de I+D, 2008-2011 and the Instituto de Salud Carlos III - Subdirección General de
Evaluación y Fomento de la Investigación, PI10/01403, cofinanced by ERDF. The Isidro Parga Pondal program of the Xunta de Galicia (Spain) supported the work
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Introduction
Reducing sugars can react non-enzymatically with the amino
groups of protein to form Amadori products. These early glycation
products undergo further complex reaction such as rearrange-
ment, dehydration, and condensation to become irreversibly cross-
linked, heterogeneous fluorescent derivatives, termed advanced
glycation end products (AGEs) [1]. The binding of AGEs with
their receptor (RAGE) results in diverse responses, including
altered gene expression and cell migration and proliferation and
activation of signalling pathways that are considered to play a
pivotal role in the pathogenesis of atherosclerosis, heart failure,
and other vascular complications [2]. Although the role of AGEs-
RAGE interaction is deemed of great importance in diabetic
vasculopathy, a growing body of evidence indicates that this
signalling pathway can also play a role in non-diabetic athero-
sclerosis [3]. This hypothesis has been tested in rodent models of
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exaggerated neointimal expansion – a hallmark of coronary
stenosis – which is triggered by chronic hyperglycaemia or
oxidative stress; and provided the first clue that RAGE-dependent
mechanisms of inflammatory and tissue perturbation were not
limited to the diabetic state [4]. Blockade of RAGE significantly
decreased vascular expression of adhesion molecules, pro-throm-
botic species as tissue factor, and diminished antigen activity of
matrix metalloproteinases [5,6].
A soluble form of RAGE (sRAGE) can be measured in
peripheral blood, which could result from the expression of a
RAGE gene splice variant that encodes an amino-terminally
truncated form of the receptor (esRAGE) and/or from the
cleavage of the native membrane receptor (cRAGE) [7,8]. The
sRAGE levels have been found to be elevated in coronary artery
diseases cases, as well as in patients with heart failure [9,10].
In this study, we sought to gain a greater conceptual insight into
the relationship between advanced glycation and coronary artery
disease. In this regard, we explored the relationship between
fluorescent AGEs and sRAGE with the presentation form and
severity of acute coronary syndrome (ACS), the systolic function
and the extension of coronary artery disease. Furthermore we
investigated the predictive accuracy of fluorescent AGE and
sRAGE for major adverse cardiac events in patients with acute
myocardial infarction, both in-hospital and at the 1-year follow-




Patients have been included in the study after written informed
consent and the study and all the protocols used for the research
were approved by the Ethical Committee for Clinical Investiga-
tions of Galicia (Spain) in accordance with the principles expressed
in the 1975 Declaration of Helsinki.
Study Population
Between October 2009 and January 2011, we performed an
analysis of prospective data in consecutive patients admitted to our
coronary care unit (CCU) with ACS and fitting our inclusion
criteria. ACS was defined according to the European Society of
Cardiology Guidelines [11]. Patients were classified as having
acute myocardial infarction (AMI) with ST-segment elevation
(STEMI) or ACS without ST-segment elevation (NSTE-ACS)
[UA: unstable angina; NSTEMI: non-ST elevation AMI). The
exclusion criteria of this study included pregnancy, previous
myocardial infarction, a history of heart failure, myocardiopathy
or moderate/severe valvular heart disease, prior stroke, arterial or
venous thrombo-embolic disease, peripheral artery disease,
impaired renal function (glomerular filtrate rate by MDRD-
4,60 mL/min/1.73 m2), liver dysfunction, active or recent
infections (last month), a history of inflammatory or connective
tissue disorders, chronic or occasional (last 3 weeks) anti-
inflammatory or corticosteroid treatment, cancer, haematological
disorders, and previous major trauma or surgery (within 3
months). Thus, the final cohort was composed of 215 patients.
Figure 1 represents a consort diagram of the population included
in the study.
Risk Scores
The GRACE [12] [Global Registry of Acute Coronary Events]
(for in-hospital and for 6-months risk of death and myocardial
infarction), TIMI [13,14] [Thrombolysis in Myocardial Infarction]
and PURSUIT [15] [Platelet glycoprotein IIb/IIIa in Unstable
angina: Receptor Suppression Using Integrilin Therapy] risk
scores were calculated from the initial clinical history and
electrocardiogram, as well as from the values of laboratory
parameters collected at admission, as a measurement of death risk.
The complexity of coronary artery disease was evaluated by
SYNTAX score [16]. All risk scores were calculated retrospec-
tively (using prospective data) and separately by two persons who
were blinded to the study results (agreement .98%).
Measurement of Serum AGEs and sRAGE
AGEs were measured by quantitative fluorescence spectroscopy
analysis of plasma according to the method of Munch et al [17].
By this method, we could measure some different AGE
modifications at a time (crossline, fluorolink, pyrropyridine,
vesperlysine, etc.), for which there are no immunological-based
methods available nowadays. Plasma was aliquoted into black 96-
well plates in duplicate and fluorescence (360/40:460/40 nm;
excitation:emission) was measured in a multi-mode microplate
reader (Synergy 2, Biotek, Potton, United Kingdom) at room
temperature to estimate the levels of fluorescent AGEs. Readings
were subtracted from those of plasma-free wells to obtain
measurements in arbitrary units (AU) and the mean of duplicated
readings calculated. Plasma sRAGE levels were determined using
a commercially available enzyme-linked immunosorbent assay kit
(Quantikine; R&D systems, Minneapolis, MN, USA) according to
the manufacturers protocol. Measurements were performed in
duplicate and the results were averaged. This intra-assay and
inter-assay coefficients of variation values were ,5% and ,8%,
respectively.
Follow-up and Endpoints
Events were defined as either cardiac death, as noted and
confirmed by review of the death certificate and hospital chart or
physician’s records, non-fatal myocardial infarction, as evidenced
by the appropriate combination of symptoms, electrocardiogram,
and enzyme changes, or admission due to heart failure. The strong
study endpoint was the combination of cardiac death, reinfarction
or heart failure. This endpoint was analysed both at the in-hospital
phase and during the follow-up. The follow-up time was 366 days
(inter-quartile range: 273–519 days). During the observation
period, there was no dropout.
Figure 1. Consort diagram of the population included in the
study.
doi:10.1371/journal.pone.0074302.g001
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Table 1. Baseline characteristics of study population, stratified by presence of in-hospital and follow-up cardiac events.










Age (years) 62.7613.0 66.9610.5 62.3613.1 0.140 66.0611.6 62.0613.2 0.129
Female, % 24.2 47.4 21.9 0.013 13.8 26.0 0.156
Medical history
Current smoking, % 34.9 26.3 35.7 0.523 34.5 35.4 0.459
Diabetes, % 25.6 36.8 24.5 0.239 34.5 23.8 0.217
Hypertension, % 46.0 47.4 45.9 0.904 62.1 44.8 0.083
Dyslipidaemia, % 44.2 57.9 42.9 0.208 48.3 43.1 0.602
On admission data
NST-ACS, % 7.4 5.3 7.7 0.356 3.4 8.3 0.362
STEMI, % 47.4 63.2 45.9 0.151 55.2 47.0 0.411
Killip class $ II, % 13.5 68.4 8.2 0.001 31.0 9.9 0.002
Atrial fibrillation, % 7.4 5.3 7.7 0.705 13.8 6.5 0.177
Laboratory data
Haemoglobin (g/dL) 14.361.6 13.361.9 14.561.5 0.003 13.661.7 14.561.5 0.009
Blood cell count (/mL) 9.7 (8.0–12.6) 9.7 (7.9–12.5) 11.7 (8.1–17.2) 0.078 9.8 (8.1–12.5) 9.4 (7.5–14.2) 0.893
LDL (mg/dL) 116.3639.0 121.4653.6 115.9637.5 0.694 115.6641.8 117.3638.6 0.843
TPI peak (ng/mL) 13.9 (3.3–59.2) 12.9 (3.1–52.2) 49.1 (10.2–154.5) 0.021 12.3 (2.7–50.4) 57.9 (7.2–156.3) 0.007
Risk Scores
TIMI 2.761.1 3.361.0 2.661.0 0.011 2.961.0 2.661.1 0.110
PURSUIT 9.664.1 11.663.6 9.464.2 0.025 11.563.2 9.364.2 0.002
GRACE 135.3637.1 166.7646.6 132.3634.7 0.001 115.4630.3 97.2628.7 0.002
SYNTAX 14.267.3 18.665.6 13.867.4 0.006 16.168.4 13.767.2 0.118
Glycations products
Glucose (mg/dL) 124.0 (104.0–170.0) 177.0 (139–0–347.0) 122.0 (103.2–158.0) 0.001 151.0 (113.5–260.5) 122.0 (103.5–157.5) 0.025
Fructosamine (mg/dL) 172.0 (148.0–209.2) 180.0 (139.0–335.5) 172.0 (148.0–208.5) 0.461 205.0 (159.0–311.0) 170.0 (148.0–197.0) 0.052
HbA1c, % 5.7 (5.4–6.2) 5.7 (5.5–8.4) 5.7 (5.4–6.1) 0.295 5.9 (5.5–8.0) 5.6 (5.4–6.0) 0.015
Fluorescent AGE (AU) 44.0 (34.0–55.5) 43.0 (38.0–51.0) 44.2 (33.6–56.0) 0.727 51.0 (40.2–157.7) 43.0 (32.7–53.2) 0.002
sRAGE (pg/mL) 833.0 (539.3–1256.5) 1709.0 (1130.0–
2398.0)
809.3 (522.2–1126.0) 0.001 985.0 (533.7–1702.0) 827.0 (523.7–1251.0) 0.388
Procedural characteristics
LVEF #45%, % 18.1 63.2 13.8 0.001 44.8 13.8 0.001
Multi-vessel disease, % 51.2 63.2 50.0 0.273 62.1 48.6 0.179
PCI, % 78.2 78.9 78.1 0.929 75.9 79.0 0.702
Complete revascularisation,% 80.0 78.9 89.5 0.276 78.3 80.3 0.823
Discharge Treatments
Aspirin, % 100 – – – 100 100 –
Clopidogrel, % 99.0 – – – 100 98.9 0.564
B-blockers, % 74.3 – – – 72.4 74.6 0.804
ACEI/ARB II, % 77.7 – – – 86.2 76.3 0.431
Statins, % 94.3 – – – 95.5 94.2 0.809
ACEI/ARB II: Angiotensin-converting Enzyme Inhibitors/Angiotensin II receptor blockers. BMI: Body Mass Index. LVEF: Left Ventricular Ejection Fraction. PCI:
Percutaneous Coronary Intervention. STEMI: ST-elevation myocardial infarction. UA: Unstable Angina.
doi:10.1371/journal.pone.0074302.t001
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Statistical Analysis
The statistical analyses were performed with SPSS (Statistical
Package for the Social Sciences), version 17.0. The categorical or
dichotomous variables were expressed as absolute values and
percentages, and were compared with the Pearson X2 test. The
continuous variables were described as the mean 6 standard
deviation (SD) when normally distributed or as the median and
inter-quartile range for non-parametric data. Student t test was
used for the comparisons of continuous variables between groups
of patients. Continuous data from .2 groups were compared with
ANOVA test. Receiver operating characteristic (ROC) curve
analysis was performed to establish the diagnosis value of the
different biomarkers to predict cardiac events. A binomial logistic
regression model (with backward stepwise analysis) was used to
evaluate the independent role of AGE and sRAGE as predictors of
in-hospital adverse prognosis. A Cox proportional hazard analysis
was carried out to assess the independent role of AGEs and
sRAGE for predicting mortality during the follow-up. Adjusted
odds, hazard ratios and 95% confidence intervals (CI) were
presented. Kaplan Meier curves were performed to evaluate the
prognostic value during follow-up of AGEs and sRAGE. Their




The baseline characteristics of the final cohort, as well as the
detailed characteristics of the events group, are shown in Table 1.
The mean age was 62.7613.0 years (24.2% female). 47.4% had a
diagnosis of STEMI and 52.6% had NSTEMI (UA: 7.4%).
The mean circulating fluorescent AGEs and sRAGE levels were
44.0 (34.0–55.5) AU and 833.0 (539.3–1256.5) pg/mL, respec-
tively. There was no significant relation between these two
variables (p = 0.705) and none of them were associated with
diabetes mellitus.
Glycation Products and ACS
There were no significant differences in fluorescent AGEs and
sRAGE plasma levels among the different ACS subtypes (Figure 2)
(AGE = 48.7 (41.7–52.6), 45.5 (32.0–62.2) and 42.5 (33.7–51.0)
AU vs. sRAGE = 836.7 (438.0–1308.5), 988.0 (602.2–1290.0) and
777.0 (517.3–1118.0) pg/mL, p.0.05, for UA, NSTEMI and
STEMI, respectively), although the percentage of NST-ACS
patients (NSTEMI and UA) were higher in the higher quartiles of
fluorescent AGEs (Table 2).
Patients were divided according to the fluorescent AGEs
quartiles at admission (Q1#34.0 AU; Q2:34.1–44.0 AU;
Q3:44.1–55.5 AU; and Q4.55.5 AU; Table 2). There was a
slight trend to more smoking habits and more hypertension in the
upper quartiles of fluorescent AGEs (p = 0.097 and p = 0.080,
respectively). There was no association between fluorescent AGEs
and cholesterol. Fluorescent AGEs tended to correlate with
fructosamine (r = 0.143, p = 0.072) and HbA1c (r = 0.129,
p = 0.082), but not with glucose levels (r = 0.091, p = 0.186). High
fluorescent AGEs levels were associated with the presence of multi-
vessel disease and more vessels affected, but not with the worst
Killip class or lower LVEF. Likewise, there was no association
between fluorescent AGEs and infarct size (troponin I peak).
Patients were also divided on the basis of sRAGE quartiles at
admission (Q1#538.4 pg/mL; Q2:538.5 to 826.9 pg/mL;
Q3:827.0–1255.0 pg/mL; and Q4.1255.0 pg/mL; Table 3).
No differences among the distribution of classical risk factors
were found between each quartil of sRAGE levels. Neither the
lipid profile nor glycaemic values (glucose, fructosamine, HbA1c,
and AGEs) were related to sRAGE levels. There was a significant
increase in sRAGE levels in relation to the severity of Killip
functional class at admission. The percentage of left ventricular
dysfunction and atrial fibrillation was significantly higher with
increasing sRAGE levels (p = 0.038 and p = 0.045, respectively),
whereas the mean values of haemoglobin were lower. Infarct size,
as measured by peak troponin I, was correlated with sRAGE levels
(r = 0.306, p,0.001). Clinical outcomes (in-hospital and follow-up
cardiac events) are displayed in Table 4.
No significant association was found between fluorescent AGEs
and sRAGE levels and treatment at discharge (anti-platelets, B-
blockers, ACEI/ARB-2 and statins).
Glycation Products and Increasing Cardiovascular Risk
Clinical outcomes are shown in Table 4. Nineteen patients
(8.8%) presented cardiac events during the in-hospital phase (5
cardiac deaths, 7 re-infarctions and 9 new-onset heart failure).
During the follow-up, 29 patients (13.8%) presented cardiac events
(4 cardiac death, 17 re-infarctions and 12 heart failure admissions).
Figure 2. Relation of fluorescent AGEs and sRAGE with the type
of ACS. Box plots for fluorescent AGE (A) and sRAGE (B) plasma levels
for non ST-segment elevation acute coronary syndrome patients (NST-
ACS) and ST-segment elevation myocardial infarction (STEMI).
doi:10.1371/journal.pone.0074302.g002
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In-hospital cardiac events were significantly associated with
higher sRAGE levels (p = 0.001), but not with long-term cardiac
events (p = 0.365). This is consistent with significant correlations
between sRAGE levels and the predicted cardiovascular in-
hospital risk for each of the four risk scoring schemes as follows:
TIMI (r = 0.210; p = 0.002), PURSUIT (r = 0.166; p = 0.015) and
GRACE (r = 0.194; p = 0.004; Figure 3).
Regarding fluorescent AGE, the opposite was seen to occur
[there was a significant increase in AGEs levels in patients with
follow-up cardiac events (Figure 4), but not in patients with in-
hospital events (p = 0.965)]. Fluorescent AGEs were not correlated
with risk scores, including GRACE scores for 6-months events
(r = 0.042; p = 0.545).
To predict in-hospital events, we found that the area under the
curve (AUC) of sRAGE was 0.84 (95% CI: 0.75–0.93). The best
cut-off level for sRAGE was 1094.5 pg/mL, with a sensitivity of
84.2% and a specificity of 73.5% (Figure 5A), as well as a negative
predictive value (NPV) of 99.0% and a positive predictive value
(PPV) of 15.7%. For fluorescent AGEs, the AUC was not good
0.52 (95% CI 0.41–0.64).
In relation to follow-up events, the AUC of fluorescent AGE
was 0.68 (95% CI 0.57–0.79), higher than the AUC of sRAGE
that was 0.55 (0.43–0.67). The cut-off level of fluorescent AGEs,
which best predicts an unfavourable follow-up, was 46.8 AU, with
a sensitivity of 69.0% and a specificity of 60.8% (Figure 5B), along
with an NPV of 92.4% and a PPV of 28.6%.
After multivariate analysis correcting for sex, LVEF, glucose
levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was
significantly associated with in-hospital prognosis (events risk
increase 10% per 10 pg/mL), whereas fluorescent AGEs were
significantly associated with long-term prognosis (events risk
increase 12% per 1 AU; Table 5).
Discussion
This is the first study to investigate the prognostic value of
fluorescent AGEs and sRAGE in ACS patients. Elevated values of
sRAGE were independently associated with a worse in-hospital
prognosis, whereas high fluorescent AGE levels were associated
with more events during follow-up. Both parameters reflect
different risk measures, and their association with clinical
outcomes is probably due to different mechanisms. Although it
has been recently shown that sRAGE correlated with troponin
levels in ACS [18], its prognostic value in these patients has not
been studied yet.
In the context of an ACS, sRAGE is mainly a marker of
inflammatory damage [8,19]. However, to understand the role of
sRAGE we must first note that sRAGE is composed of two
different types of molecules, which probably have different
prognostic and pathophysiological implications that may explain
the controversy about the utility of sRAGE [20]. It is known that
levels of sRAGE depend on the sRAGE directly secreted by cells
(esRAGE) and on the sRAGE resulting from cellular transmem-
Table 2. Baseline characteristics based on quartiles of fluorescent AGE.








(n = 54) p value
Demographic data
Age (years) 63.7611.3 62.4611.8 61.9613.3 62.8615.3 0.911
Female, % 22.6 29.6 21.8 22.6 0.758
Medical history
Current smoking, % 22.6 37.0 43.6 35.8 0.097
Diabetes, % 20.8 27.8 25.5 28.3 0.803
Hypertension, % 47.2 31.5 54.5 50.9 0.080
Dyslipidaemia, % 39.6 38.9 49.1 49.1 0.550
On admission data
STEMI, % 47.2 61.1 47.3 34.0 0.048
Killip class $ II, % 15.1 16.7 12.7 9.4 0.715
Atrial fibrillation, % 9.4 7.4 3.6 9.4 0.622
Laboratory
Haemoglobin (g/dL) 14.461.4 14.461.4 14.561.5 14.262.0 0.686
Blood cell count (/mL) 10.0 (7.6–12.1) 10.3 (8.6–13.5) 9.9 (8.1–12.4) 9.4 (7.8–12.4) 0.844
LDL (mg/dL)* 112.8635.9 122.1642.6 116.1634.3 114.2642.7 0.666
TPI peak (ng/mL)* 21.4 (3.1–69.4) 18.9 (2.3–54.4) 11.8 (3.8–70.0) 10.8 (3.3–41.4) 0.595
Procedural characteristics
LVEF ,45%, % 20.8 24.1 17.0 18.1 0.320
Multi-vessel disease, % 43.4 42.6 60.0 64.2 0.046
Complete revascularisation, % 86.4 81.3 81.6 70.5 0.290
Abbreviations as in table 1.
doi:10.1371/journal.pone.0074302.t002
Prognosis Value of AGE and sRAGE in ACS
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74302
brane receptor cleavage (cRAGE) [1]. Controverting results have
been reported about the physiopathological role of sRAGE on
coronary artery disease (CAD). Falcone et al., in a study with 328
non-diabetic patients, reported an association between low levels
of sRAGE and the presence of CAD [3]. On the contrary, in
diabetic patients, high levels of sRAGE correlate with the presence
of CAD, as reported by Nakamura et al. [21], and recently
confirmed by the results of the CARDS trial [9]. This controversy
could come from the absence of data about the specific
contribution of each sRAGE form to the total amount of sRAGE
in diabetes and CAD. Our hypothesis is that diabetes could modify
the percentages of esRAGE and cRAGE and that the former
could be protective whereas the latter could serve as a disease
biomarker. Further investigations are needed to clarify this
question. Several studies correlated sRAGE levels with inflamma-
tory markers, such as TNF-alpha, high mobility group box 1
(HMGB1), caspase 3 or interleukin-6 [22]. The role of inflamma-
tion in the development of CAD and in plaque destabilisation is
becoming increasingly well recognised. An inflammatory response
is often found at the site of plaque rupture, and several
Table 4. Clinical outcomes based on quartiles of sRAGE and fluorescent AGE.
PROGNOSTIC VALUE sRAGE levels Fluorescent AGE levels
Q1 Q2 Q3 Q4 p Q1 Q2 Q3 Q4 p
In-Hospital Events 0.0 3.8 5.6 25.9 0.001 7.5 11.1 12.7 3.8 0.365
Cardiac death 0.0 5.7 1.9 1.9 0.263 3.8 1.9 1.8 1.9 0.885
Reinfarction 0.0 0.0 3.7 9.3 0.020 1.9 3.7 5.5 1.9 0.680
Heart Failure 0.0 0.0 0.0 18.5 0.001 3.8 5.6 9.1 0.0 0.156
Follow-up events 14.8 12.0 13.2 15.1 0.965 5.7 9.6 17.0 23.1 0.048
Cardiac death 1.9 2.0 3.8 0.0 0.568 1.9 0.0 1.9 3.8 0.560
Reinfarction 11.1 6.0 7.5 7.5 0.802 1.9 5.8 9.4 15.4 0.073
Heart Failure 5.6 4.0 7.5 7.5 0.895 3.8 3.8 5.7 9.6 0.537
doi:10.1371/journal.pone.0074302.t004
Table 3. Baseline characteristics based on quartiles of sRAGE.








(n = 54) p value
Demographic data
Age (years)* 60.7612.9 61.9612.3 62.3614.7 65.8611.6 0.201
Female, % 16.7 20.8 25.9 33.3 0.207
Medical history
Current smoking, % 33.3 32.1 38.9 35.2 0.535
Diabetes, % 22.2 20.8 25.9 33.3 0.444
Hypertension, % 40.7 47.2 46.3 50.0 0.806
Dyslipidaemia, % 38.9 41.5 51.9 44.4 0.561
On admission data
STEMI, % 53.7 58.5 38.9 38.9 0.085
Killip class $ II, % 9.3 11.3 7.4 25.9 0.019
Atrial fibrillation, % 0.0 5.7 13.0 11.1 0.045
Laboratory
Haemoglobin (g/dL) 14.761.4 14.761.3 14.361.7 13.861.7 0.004
Blood cell count (/mL) 10.6 (8.2–13.3) 9.9 (8.3–13.7) 9.2 (7.3–11.4) 9.4 (8.1–12.5) 0.270
LDL (mg/dL) 123.8641.1 119.1639.1 106.7631.9 115.8642.3 0.173
TPI peak (ng/mL) 16.6 (5.3–41.2) 31.1 (4.2–105.1) 12.4 (2.0–46.0) 9.4 (3.6–108.6) 0.338
Procedural characteristics
LVEF ,45%, % 11.1 11.3 20.4 29.6 0.038
Multi-vessel disease, % 57.4 49.1 46.3 57.4 0.546
Complete revascularisation, % 77.3 79.6 84.1 79.2 0.875
Abbreviations as table 1.
doi:10.1371/journal.pone.0074302.t003
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investigations have correlated its degree (based on the measure-
ment of various inflammatory biomarkers) with post-infarction
mortality [23]. sRAGE was probed as an inflammatory biomarker
of plaque vulnerability in patients with myocardial infarction,
which correlated with higher troponin, but its prognostic value in
ACS has not yet been evaluated [24].
In our study, several factors may play a role in the demonstrated
association between sRAGE levels and an adverse in-hospital
prognosis. Increasing sRAGE levels were clearly associated with
worse Killip class, lower haemoglobin levels, more atrial fibrilla-
tion and more systolic left ventricular dysfunction, in addition to a
trend to present larger myocardial infarction (higher troponin peak
level) and a higher percentage of STEMI, explaining part of the
increase of in-hospital mortality. Although Basta et al. [18]
recently demonstrated that sRAGE was correlated with higher
troponin levels in ACS, sRAGE was a predictor of in-hospital
events independently of troponin levels in our study. In fact,
sRAGE levels were significantly associated with the three most
widely used risk scores in ACS (TIMI, PURSUIT, and GRACE).
Contrary to sRAGE, AGE is a marker of chronic oxidative
stress [25], but not for acute inflammatory damage, with different
characteristics in comparison to sRAGE. Whereas sRAGE is a
dynamic molecule, dependent on tissue damage [7], AGE is more
stable, so that its time-dependent variation curve is much flatter
than that of sRAGE, as determined by the fact that AGEs take
weeks to form [1]. This could explain the absence of a relationship
with the in-hospital prognosis. However, since AGE reflects the
degree of chronic oxidative stress and, secondarily, atherosclerotic
burden [6,26], it is reasonable to suppose that AGE should be
associated with a worse medium to long-term prognosis. Several
studies have demonstrated that AGEs were a marker of oxidative
damage, depending on oxidative stress for its production, and
likewise encouraged the formation of reactive oxygen species
(ROS) [25]. ROS are important contributors to cardiovascular
disease, including the events surrounding myocardial infarction.
They have been implicated in numerous cardiovascular patholo-
gies, including endothelial dysfunction or ventricular remodelling
[27]. All together could serve to explain the worse prognosis of
high levels of fluorescent AGEs after ACS over time. However,
despite being widely tested as a marker of oxidative stress, no study
analysed the prognostic and physiopathological implications of
AGEs in ACS.
In our study, the association of fluorescent AGE with the
presence of cardiac events was noticed during the follow-up.
Patients with elevated levels of fluorescent AGEs are more prone
to hypertension and smoking, which translates to a greater degree
of atherosclerosis, implying a higher percentage of multi-vessel
coronary disease and a higher percentage of NSTE-ACS.
Although this does not indicate a worse in-hospital prognosis, it
results in a greater number of events during follow-up.
Limitations
Despite the impact and enthusiasm that our results can
generate, we are aware of the limitations of our study that should
be taken into account when the results are interpreted. Mainly we
must consider that our study population, which included all
patients admitted for ACS in the coronary care unit over a 15
month period, underwent some very strict inclusion/exclusion
criteria, that supposed a significant reduction in sample size
(n = 215) with a very selective population, which determines the
statistical power of the analysis. On the other hand, fluorescent
AGEs were measured globally without specifying the type of
analysed AGE, whereas non-fluorescent AGEs were not analysed.
Fluorescent AGEs neither was correlated with levels of markers of
oxidative stress. As for the measurement of sRAGE, neither
esRAGE nor cRAGE were distinguished, and neither was
correlated with other markers of inflammatory damage. Despite
all of this, we believe that our research is of great interest for being
Figure 3. Relation of sRAGE levels and risk categories of
different ACS scores. Columns represent mean values (indicated in
numbers) for sRAGE plasma levels in each category of the indicated
scores.
doi:10.1371/journal.pone.0074302.g003
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the first to analyse the prognostic implications of fluorescent AGE
and sRAGE in the ACS spectrum.
Conclusions
This is the first study that analyses the prognostic value of the
AGE-RAGE axis in all the spectrum of ACS. As the main result,
we can conclude that elevated values of sRAGE are associated
with a worse in-hospital prognosis, whereas high fluorescent AGEs
levels are associated with more follow-up events.
Figure 4. Survival Kaplan Meier curves according fluorescent AGE quartiles. Inset represent curves magnifications about survival free of
events.
doi:10.1371/journal.pone.0074302.g004
Figure 5. Curves of sensitivity and specificity for fluorescent
AGEs and sRAGE to predict events. A) representation of sRAGE
curves to predict in-hospital events and B) fluorescent AGE curves to
predict follow-up events.
doi:10.1371/journal.pone.0074302.g005
Table 5. Multiple regression analysis for in-hospital and
follow-up events.
In-hospital events Follow-up events
Odds
Ratio CI 95% p
Hazard
Ratio CI 95% p
Female sex 2.99 0.84–10.75 0.092 0.50 0.17–1.48 0.213
Haemoglobin 0.81 0.51–1.28 0.372 0.87 0.66–1.14 0.326
Peak Troponin I 1.00 0.99–1.01 0.712 1.01 1.00–1.01 0.010
Glucose 1.008 1.01–1.02 0.009 1.00 0.99–1.01 0.156
Fluorescent AGE 0.99 0.98–1.01 0.452 1.12 1.06–1.18 0.001
sRAGE 1.10 1.04–1.17 0.002 1.00 0.97–1.03 0.930
LVEF ,45% 1.25 0.65–2.41 0.509 1.38 0.86–2.23 0.181
High risk GRACE 4.98 1.25–19.8 0.023 3.66 1.60–8.40 0.002
SYNTAX score 1.04 0.94–1.14 0.452 0.99 0.93–1.05 0.710
LVEF: Left Ventricular Ejection Fraction.
doi:10.1371/journal.pone.0074302.t005
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